We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

171 hedge funds and large institutions have $3.98B invested in Ultragenyx Pharmaceutical in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 51 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

45% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 51

17% more capital invested

Capital invested by funds: $3.39B → $3.98B (+$590M)

6% more funds holding

Funds holding: 161 → 171 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

20% less call options, than puts

Call options by funds: $10.2M | Put options by funds: $12.8M

Holders
171
Holders Change
+10
Holders Change %
+6.21%
% of All Funds
4.49%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
25
Increased
74
Reduced
51
Closed
15
Calls
$10.2M
Puts
$12.8M
Net Calls
-$2.61M
Net Calls Change
+$11.3M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$42.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$27.5M
3
Wells Fargo
Wells Fargo
California
+$22M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$19.5M
5
State Street
State Street
Massachusetts
+$12.7M

Top Sellers

1
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$43.6M
2
Millennium Management
Millennium Management
New York
-$34.7M
3
Two Sigma Investments
Two Sigma Investments
New York
-$14.5M
4
Goldman Sachs
Goldman Sachs
New York
-$14.2M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$14.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
76
Swiss National Bank
Switzerland
$3.97M +$50K +500 +1%
MOACM
77
Mutual of America Capital Management
New York
$3.76M +$49.7K +497 +2%
AQR Capital Management
78
AQR Capital Management
Connecticut
$3.71M -$168K -1,684 -5%
GH
79
GAM Holding
Switzerland
$3.65M +$1.13M +11,300 +53%
MCM
80
Moore Capital Management
New York
$3.59M +$3.2M +32,000 New
Morgan Stanley
81
Morgan Stanley
New York
$3.44M -$679K -6,794 -18%
CS
82
Candriam SCA
Luxembourg
$3.4M +$400K +4,000 +15%
Marshall Wace
83
Marshall Wace
United Kingdom
$3.33M -$4.43M -44,337 -60%
NIP
84
Nicholas Investment Partners
California
$3.27M +$568K +5,677 +24%
TD Asset Management
85
TD Asset Management
Ontario, Canada
$3.17M -$70K -700 -2%
OAM
86
Oxford Asset Management
United Kingdom
$3.17M +$2.8M +28,031 New
First Trust Advisors
87
First Trust Advisors
Illinois
$3.15M +$14.7K +147 +0.5%
MLICM
88
Metropolitan Life Insurance Company (MetLife)
New York
$2.97M – – –
PA
89
Profund Advisors
Maryland
$2.88M +$31.5K +315 +1%
Lazard Asset Management
90
Lazard Asset Management
New York
$2.87M -$206K -2,060 -7%
State Board of Administration of Florida Retirement System
91
State Board of Administration of Florida Retirement System
Florida
$2.47M +$139K +1,390 +7%
AIG
92
American International Group
New York
$2.36M -$18.1K -181 -0.9%
DekaBank Deutsche Girozentrale
93
DekaBank Deutsche Girozentrale
Germany
$2.22M +$161K +1,610 +9%
UBS Group
94
UBS Group
Switzerland
$1.92M +$699K +6,989 +69%
TAM
95
Tocqueville Asset Management
New York
$1.83M +$535K +5,350 +49%
Handelsbanken Fonder
96
Handelsbanken Fonder
Sweden
$1.79M +$1.6M +16,000 New
SO
97
STRS Ohio
Ohio
$1.69M – – –
TG
98
TCW Group
California
$1.69M -$6.1K -61 -0.4%
WMSA
99
Weiss Multi-Strategy Advisers
New York
$1.68M – – –
RFC
100
Russell Frank Company
Washington
$1.53M +$1.09M +10,951 +426%
2 3
4
5 6

RARE Hedge Fund Activity: Q4 2015 in Review

171 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2015, worth a combined $3.98B — up 17% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RARE positions and 15 closed out — a net gain of 10 holders — while 74 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $42.1M. The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $43.6M sold.

  • 171 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2015, up from 161 in Q3 2015.
  • Funds reported $3.98B of Ultragenyx Pharmaceutical stock for Q4 2015, up 17% quarter-over-quarter.
  • 25 funds opened new Ultragenyx Pharmaceutical positions in Q4 2015 and 15 closed out, a net change of +10 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2015 was Wellington Management Group, an estimated $42.1M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2015 was TPG Group Holdings (SBS) Advisors, an estimated $43.6M sold.

Based on aggregated 13F filings for Q4 2015.